These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33543516)

  • 21. Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study.
    Anguita Sánchez M; Bertomeu Martínez V; Ruiz Ortiz M; Cequier Fillat Á; Roldán Rabadán I; Muñiz García J; Badimón Maestro L; Esteve Pastor MA; Marín Ortuño F;
    Rev Esp Cardiol (Engl Ed); 2020 Jan; 73(1):14-20. PubMed ID: 31160265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study.
    Staerk L; Fosbøl EL; Lamberts M; Bonde AN; Gadsbøll K; Sindet-Pedersen C; Holm EA; Gerds TA; Ozenne B; Lip GYH; Torp-Pedersen C; Gislason GH; Olesen JB
    Eur Heart J; 2018 May; 39(19):1698-1705a. PubMed ID: 29165556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation.
    Zoppellaro G; Granziera S; Padayattil Jose S; Denas G; Bracco A; Iliceto S; Pengo V
    Expert Opin Drug Saf; 2015 May; 14(5):683-95. PubMed ID: 25803739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patients aged 90 years or older with atrial fibrillation treated with oral anticoagulants: A multicentre observational study.
    Giustozzi M; Vedovati MC; Verso M; Scrucca L; Conti S; Verdecchia P; Bogliari G; Pierpaoli L; Agnelli G; Becattini C
    Int J Cardiol; 2019 Apr; 281():56-61. PubMed ID: 30712846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a "Real-world" Nationwide Registry: Insights From the FANTASIIA Study.
    Ortiz MR; Muñiz J; Esteve-Pastor MA; Marín F; Roldán I; Cequier A; Martínez-Sellés M; Saldivar HG; Bertomeu V; Anguita M
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):316-323. PubMed ID: 32228180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants.
    Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A
    BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence and consequences of resuming oral anticoagulant therapy following hematuria and risks of ischemic stroke and major bleeding in patients with atrial fibrillation.
    Wang CL; Wu VC; Huang YT; Chen YL; Chu PH; Kuo CF; Wen MS; Chang SH
    J Thromb Thrombolysis; 2021 Jan; 51(1):58-66. PubMed ID: 32409936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
    Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
    J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
    [No Abstract]   [Full Text] [Related]  

  • 31. Racial Disparity in the Prescription of Anticoagulants and Risk of Stroke and Bleeding in Atrial Fibrillation Patients.
    Tedla YG; Schwartz SM; Silberman P; Greenland P; Passman RS
    J Stroke Cerebrovasc Dis; 2020 May; 29(5):104718. PubMed ID: 32122777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of direct acting oral anticoagulants and vitamin K antagonists in nonvalvular atrial fibrillation - a network meta-analysis of real-world data.
    Hirschl M; Kundi M
    Vasa; 2019 Mar; 48(2):134-147. PubMed ID: 30376416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation.
    Seiffge DJ; Paciaroni M; Wilson D; Koga M; Macha K; Cappellari M; Schaedelin S; Shakeshaft C; Takagi M; Tsivgoulis G; Bonetti B; Kallmünzer B; Arihiro S; Alberti A; Polymeris AA; Ambler G; Yoshimura S; Venti M; Bonati LH; Muir KW; Yamagami H; Thilemann S; Altavilla R; Peters N; Inoue M; Bobinger T; Agnelli G; Brown MM; Sato S; Acciarresi M; Jager HR; Bovi P; Schwab S; Lyrer P; Caso V; Toyoda K; Werring DJ; Engelter ST; De Marchis GM;
    Ann Neurol; 2019 Jun; 85(6):823-834. PubMed ID: 30980560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation.
    Osmancik P; Herman D; Neuzil P; Hala P; Taborsky M; Kala P; Poloczek M; Stasek J; Haman L; Branny M; Chovancik J; Cervinka P; Holy J; Kovarnik T; Zemanek D; Havranek S; Vancura V; Opatrny J; Peichl P; Tousek P; Lekesova V; Jarkovsky J; Novackova M; Benesova K; Widimsky P; Reddy VY;
    J Am Coll Cardiol; 2020 Jun; 75(25):3122-3135. PubMed ID: 32586585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impaired kidney function at ED admission: a comparison of bleeding complications of patients with different oral anticoagulants.
    Müller M; Traschitzger M; Nagler M; Arampatzis S; Exadaktylos AK; Sauter TC
    BMC Emerg Med; 2021 Sep; 21(1):105. PubMed ID: 34536992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Zirlik A; Bode C
    J Thromb Thrombolysis; 2017 Apr; 43(3):365-379. PubMed ID: 27896543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bleeding risks associated with anticoagulant therapies after percutaneous coronary intervention in Japanese patients with ischemic heart disease complicated by atrial fibrillation: A comparative study.
    Nakamura M; Yamashita T; Hayakawa A; Matsumoto T; Takita A; Hasegawa C; Uchino K; Sekine T; Iizuka T; Tanabe H; Kogure S
    J Cardiol; 2021 Feb; 77(2):186-194. PubMed ID: 32943280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease.
    Kooiman J; van Rein N; Spaans B; van Beers KA; Bank JR; van de Peppel WR; del Sol AI; Cannegieter SC; Rabelink TJ; Lip GY; Klok FA; Huisman MV
    PLoS One; 2014; 9(5):e94420. PubMed ID: 24817475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using the Case-Crossover Design to Assess Short-Term Risks of Bleeding and Arterial Thromboembolism After Switching Between Oral Anticoagulants in a Population-Based Cohort of Patients With Atrial Fibrillation.
    Hellfritzsch M; Wang SV; Grove EL; Gagne JJ; Hallas J; Pottegård A
    Am J Epidemiol; 2020 Dec; 189(12):1467-1477. PubMed ID: 32639512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.